Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches
This article was originally published in The Tan Sheet
Executive Summary
FDA likely will face a legal challenge regardless of whether the agency decides to implement mandated Rx-to-OTC switches or chooses a more indirect policy yielding similar results, according to comments made by Aventis and Pfizer executives
You may also be interested in...
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
Generic PPIs Look For Long-Term Formulary Benefit From Prilosec OTC
Price pressures caused by the availability of Procter & Gamble's Prilosec OTC may offer potential upsides for generic omeprazole offerings regarding favorable formulary status, according to insurers
Allegra Sales Decline Will Not Prompt OTC Switch, Aventis Says
Decreasing Allegra sales in the face of increased competition from OTC antihistamines will not lead Aventis to pursue a switch for the drug, the firm stated during an Oct. 30 call on third-quarter results